Get started
Author

Sandra X. Franco

Observed names: S.X. Franco Millan, Sandra Franco, Sandra Franco Millan, Sandra X. Franco Millan, Sandra Ximena Franco Millan
ORCID: 0009-0001-1690-1941
Observed ORCID: 0009-0001-1690-1941
OpenAlex ID: A5104312582
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
2023 · Josep M Llovet, Masatoshi Kudo, et al. · The Lancet Oncology · 509
PDF
6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)
2024 · Fatima Cardoso, Shani Paluch-Shimon, et al. · The Breast · 278
Challenges and Opportunities for Cancer Clinical Trials Development in Latin America
2025 · Juan Manuel Garzón-Dangond, Oscar Arrieta, et al. · JCO Global Oncology · 3
PDF
Multilocus Inherited Neoplasia Alleles Syndrome in a Patient With BRCA2‐Associated Breast Cancer and MLH1‐Related Lynch Syndrome
2026 · Vaneza Avila-Rodriguez, Alejandro Ruiz-Patiño, et al. · Case Reports in Oncological Medicine · 1
Cáncer de mama luminal: estado del arte
2023 · María A. Bravo-Garzón, William A. Mantilla, et al. · Medicina · 1
8th International consensus guidelines for the management of advanced breast cancer (ABC8 guidelines)
2026 · Fatima Cardoso, Joana Mourato Ribeiro, et al. · The Breast
312P Population-level impact of neoadjuvant and adjuvant HER2-targeted therapies for non-metastatic breast cancer in Colombia
2026 · A.M. Osorio, S.X. Franco Millan, et al. · ESMO Open
Works count: 7
Citation count: 792
H-index: 3
I10-index: 2
Year
Topic
Type